SIGLEC

Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy

Retrieved on: 
Thursday, February 1, 2024
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Geographic atrophy, SIGLEC, Part, AMD, Inflammation, Patient, Senior, Safety, HERE, Therapy, Pharmaceutical industry

“In Part 1 of SIGLEC, we found that AVD-104 had a positive safety profile, and that patients with GA dosed with AVD-104 showed BCVA improvements at 3 months (Found HERE ).

Key Points: 
  • “In Part 1 of SIGLEC, we found that AVD-104 had a positive safety profile, and that patients with GA dosed with AVD-104 showed BCVA improvements at 3 months (Found HERE ).
  • Patients will be dosed for 12 months, with the opportunity to remain in the study for an additional 12 months.
  • Those assigned to treatment with AVD-104 will receive either low-dose AVD-104, high-dose AVD-104, or the active comparator.
  • Numerous other visual functional and anatomic efficacy measures will also be explored and compared between AVD-104 and the active comparator.

Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy

Retrieved on: 
Tuesday, January 16, 2024
Research, General Health, Pharmaceutical, Optical, Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, Neurology, Other Science, Health, Senior, Patient, Therapy, Part, Geographic atrophy, SIGLEC, Safety, AMD, Inflammation, Visual acuity, Pharmacokinetics, Pharmaceutical industry

All patients in Part 1 of the trial tolerated a single dose of AVD-104 at month 3, and no drug-related ocular or systemic severe adverse reactions were observed.

Key Points: 
  • All patients in Part 1 of the trial tolerated a single dose of AVD-104 at month 3, and no drug-related ocular or systemic severe adverse reactions were observed.
  • A greater reduction in GA lesion progression at 3 months was seen when compared to historical standard-of-care outcomes.
  • Significant best corrected visual acuity (BCVA) gains were observed after a single AVD-104 injection and were sustained at 3 months.
  • Numerous other visual functional and anatomic efficacy measures will also be explored and compared between AVD-104 and the active comparator.

Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent

Retrieved on: 
Monday, October 23, 2023
Technology, Research, Diabetes, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Patient, SIGLEC, Macrophage, Injection, Microglia, Geographic atrophy, Inflammation, Factor, Senior, Pharmacokinetics, Growth, Clinical trial, American Academy, GA, American Academy of Ophthalmology, Aviceda, Safety, Therapy, Pharmaceutical industry, Ophthalmology

By repolarizing these immune cells to a resolution state, AVD-104 effectively reduces inflammation.

Key Points: 
  • By repolarizing these immune cells to a resolution state, AVD-104 effectively reduces inflammation.
  • Additionally, it enhances the activity of complement factor H, a crucial regulator of the complement cascade, to better regulate overamplification of the alternative complement cascade.
  • We are excited by our data to date and look forward for our larger clinical trial to start next month.”
    The SIGLEC U.S.
  • Part 1 of the trial is a multi-center, open label safety and dose escalation study that enrolled 30 participants.

Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety in the Treatment of Geographic Atrophy Secondary to Macular Degeneration

Retrieved on: 
Wednesday, October 11, 2023
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Choroidal neovascularization, SIGLEC, Nanoparticle, Retinal vasculitis, Animal, Safety, University, University of California, CNV, Therapy, AMD, Pharmacovigilance, Clinical trial, Infection, Patient, Geographic atrophy, Pharmaceutical industry, Telescopic sight, Ophthalmology, Macrophage

The Phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-related macular degeneration (AMD).

Key Points: 
  • The Phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-related macular degeneration (AMD).
  • Notably, no drug-related ocular inflammation, retinal vasculitis, choroidal neovascularization, infection, or optic nerve abnormalities were observed in any eyes.
  • Treatment also reduced choroidal neovascular (CNV) lesion sizes comparable to aflibercept in a laser induced CNV mouse model.
  • “We are eager for the continuation of parts 1 and 2 of the US Phase 2/3 SIGLEC clinical trial for patients with AMD-related geographic atrophy.

Aviceda To Present at Major European Healthcare Conferences Highlighting AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration

Retrieved on: 
Monday, September 25, 2023
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Clinical Trials, Infection, SIGLEC, AMD, Aviceda, Safety, Retinal vasculitis, Cohort, Clinical trial, Geographic atrophy, GA, Inflammation, Part, Disulfiram-like drug, Panel, MD, Physician, Patient, Modulation, Nanoparticle, Therapy, Society, Choroidal neovascularization, Pharmaceutical industry, Macrophage

19:00-19:30, Mohamed Genead, MD, Panel 8 - Novel Therapeutics for Geographic Atrophy: How do we measure success for physicians, patients, and payers?

Key Points: 
  • 19:00-19:30, Mohamed Genead, MD, Panel 8 - Novel Therapeutics for Geographic Atrophy: How do we measure success for physicians, patients, and payers?
  • The study evaluated patients with GA secondary to AMD from Cohorts 1 and 2 in the Phase 2/3 (Part 1) SIGLEC trial.
  • Notably no drug related inflammation, retinal vasculitis, choroidal neovascularization, infection, or optic nerve abnormalities were seen in any eyes.
  • Though the SIGLEC trial recently began in June of this year, Aviceda has already completed the dose-escalation enrollment for all cohorts in Part 1.

Aviceda Announces Podium Presentations on AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, at American Society of Retina Specialists (ASRS) and the OIS Retina Innovation Summit Meetings

Retrieved on: 
Wednesday, July 19, 2023
Technology, Research, Nanotechnology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Optical, Science, Thomas Jefferson University, AMD, Geographic atrophy, SIGLEC, Therapy, Safety, Society, GA, ASRS, Aviceda, Pharmaceutical industry, Ophthalmology

“We are excited about Aviceda's presence at ASRS this year.

Key Points: 
  • “We are excited about Aviceda's presence at ASRS this year.
  • AVD-104 was engineered with dual mechanism of action to target both the cellular immune dysfunction and complement implicated in AMD progression.
  • “We look to usher in a new paradigm for safer and effective treatment of GA associated with AMD,” said Mohamed Genead, M.D., Chief Executive Officer & Co-Founder, Aviceda Therapeutics.
  • “I am excited to present the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, in the Phase 2 SIGLEC Trial

Retrieved on: 
Thursday, June 1, 2023
Science, Biotechnology, Nanotechnology, Research, Pharmaceutical, Health, Technology, Clinical Trials, SIGLEC, Macrophage, AMD, Geographic atrophy, Hope, GA, System, Fibrosis, MD, Patient, Associate, Therapy, Neurology, Pharmaceutical industry, Aviceda

This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Key Points: 
  • This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong pre-clinical in vivo efficacy and safety profile, used for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • “I am honored to be the first to dose a new agent that we hope will usher in a generation of safe treatments for GA with better outcomes than were ever possible before,” said Dr. Abbey.
  • “AVD-104 is a potentially transformative targeted approach for patients with GA due to AMD,” said David Callanan, M.D., Chief Medical Officer of Aviceda.
  • Based on this dual mechanism and the exquisite selectivity and preclinical potency of AVD-104, we believe it could provide a profound benefit for patients in dire need of new therapies.

Elpiscience Announces Studies Presented at SITC 2022 Annual Meeting

Retrieved on: 
Monday, November 21, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Bispecific monoclonal antibody, Neoplasm, Investment, PK, Annual general meeting, TAAS, Fab, PD-L1, Eli Lilly and Company, Ligation, TME, LAG3, CDH, TAM, Cancer, Macrophage, Myelocyte, B cell, CD47, Tumor microenvironment, ADCP, LILRB2, Coronavirus Scientific Advisory Board (Turkey), Family, Mab, SITC, SIGLEC, Patient, Antibody, Fine chemical, Vaccine

Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP monoclonal antibody ES004, PD-L1/SIRP bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.

Key Points: 
  • Elpiscience Biopharmaceuticals, Inc. (Elpiscience), a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide, presented positive studies for its innovative immunotherapeutic molecules at the SITC 2022 Annual Meeting, including anti-SIRP monoclonal antibody ES004, PD-L1/SIRP bispecific antibody ES019, anti-LILRB2 monoclonal antibody ES009, anti-SIGLEC15 antibody ES012, and anti-LAG3 monoclonal antibody ES005.
  • Anti-SIRP mAb ES004 potently potentiates antibody dependent cellular phagocytosis (ADCP) activity of antibodies against tumor associated antigens (TAAs) in vitro and in vivo.
  • Elpiscience has identified a novel function of SIGLEC15 that SIGLEC15 can induce monocyte apoptosis and its inhibitory effect on T cell function is indirect.
  • To learn more about the studies, please visit Elpiscience official website https://www.elpiscience.com
    Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapy to benefit cancer patients worldwide.

Alector Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 8, 2022
IND, ALEC, Clinical trial, Safety, Immunotherapy, Survival, Standard of care, Cell, Security (finance), Forward-looking statement, Documentation, TREM2, Annual general meeting, Total, Society for Immunotherapy of Cancer, Global Health Innovative Technology Fund, SEC, Alector, U.S. Securities and Exchange Commission, Pharmacokinetics, Patient, Frontotemporal dementia, Private Securities Litigation Reform Act, Arnon Rosenthal, Neurodegeneration, Nasdaq, C9orf72, Microglia, SIGLEC, MS4A, Myelocyte, AD, Poster, Society, AbbVie, PD, GLOBE, Investment, Genetics, GSK, Biomarker, Disease, Immune system, SITC, Pharmaceutical industry, Management, Vaccine, Research

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today reported third quarter 2022 financial results and recent portfolio and business updates. As of September 30, 2022, Alector’s cash, cash equivalents and investments totaled $758.3 million.

Key Points: 
  • Sara Kenkare-Mitra, Ph.D., President and Head of Research and Development at Alector, added, Our immuno-oncology pipeline continues to advance as well.
  • Peters expertise in the human genetics of neurodegenerative disease is important to our efforts at Alector.
  • Total research and development expenses for the quarter ended September 30, 2022, were $48.3 million, compared to $43.1 million for the quarter ended September 30, 2021.
  • These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alectors forward-looking statements.

Alector Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 5, 2022
Amyotrophic lateral sclerosis, Mutation, MS4A, C9orf72, Biomarker, Safety, GFAP, CSF, CFO, Immunology, Frontotemporal dementia, International Conference on Emerging Infectious Diseases, CD33, SEC, Neurodegeneration, Forward-looking statement, AD, Immune system, Brain, Arnon Rosenthal, Plasma, Patient, Partnership, American Association, Industry, Total, Alector, CMO, Disease, GSK, SAN, Myelocyte, Lists of diseases, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, IND, Neoplasm, Cerebrospinal fluid, Security (finance), TREM2, Association, NACC, AACR, Cell, AbbVie, FTD, Microglia, Nasdaq, GLOBE, SIGLEC, Trial of the century, Therapy, Conference, HIV disease progression rates, ALEC, ALS, Management, Video game, Pharmaceutical industry, Vaccine, Granulin, Research

SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) --  Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today reported first quarter 2022 financial results and recent portfolio and business updates. As of March 31, 2022, Alector’s cash, cash equivalents, and marketable securities totaled $868.6 million.

Key Points: 
  • Data from the FTD-C9orf72 cohort builds upon the results observed in our studies to date in patients with symptomatic FTD-GRN.
  • Collaboration revenue for the quarter ended March 31, 2022, was $24.5 million, compared to $4.1 million for the same period in 2021.
  • Total research and development expenses for the quarter ended March 31, 2022, were $53.0 million, compared to $45.7 million for the quarter ended March 31, 2021.
  • These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alectors forward-looking statements.